ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0458

Single Cell Profiling Reveals a Wnt-mediated Transcriptional Gradient That Drives Inflammation in Rheumatoid Arthritis Synovial Fibroblast Pathology

Alisa Mueller1, Angela Zou1, Emily Taylor2, Triin Major2, David Gardner3, Adam Croft4, Roche Fibroblast Network Consortium5, Andrew Filer2, Christopher Buckley6, Kevin Wei1, Ilya Korsunsky1, Soumya Raychaudhuri1 and Michael Brenner7, 1Brigham and Women's Hospital, Boston, MA, 2University of Birmingham, Birmingham, United Kingdom, 3University of Birmingham, College of Medical and Dental Sciences, Birmingham, United Kingdom, 4University of Birmingham, Halesowen, United Kingdom, 5Roche Innovation Center Basel, Basel, Switzerland, 6University of Oxford, Oxford, United Kingdom, 7Brigham and Women's Hospital, Harvard Medical School, Newton, MA

Meeting: ACR Convergence 2021

Keywords: autoimmune diseases, Fibroblasts, Synovial, Inflammation, rheumatoid arthritis, Stromal Cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Abstracts: RA – Etiology & Pathogenesis (0458–0461)

Session Type: Abstract Session

Session Time: 10:30AM-10:45AM

Background/Purpose: Synovial fibroblasts are key inflammatory aggressors in rheumatoid arthritis (RA) that mediate cartilage and bone destruction, yet therapies directly targeting these cells are lacking. Our previous single cell analyses revealed multiple clusters including a fibroblast subpopulation characterized by high expression of DKK3, a Wnt-associated gene. Wnt activation can promote cell proliferation, invasion, and differentiation, making it an attractive, potentially targetable pathway in RA. Here, we report that non-canonical Wnt signaling drives a strong inflammatory gene expression signature among synovial fibroblasts.

Methods: Bulk and single cell RNA sequencing data from the Accelerating Medicines Partnership (AMP) RA/SLE Network were used to analyze expression of Wnt pathway members among synovial populations in osteoarthritis (OA) and RA. To delineate fibroblast-specific patterns of Wnt signaling, we further utilized a comprehensive stromal cell-selected single cell dataset from the Roche Fibroblast Network Consortium that includes over 73,000 fibroblasts derived from OA and RA synovium as well as other chronic inflammatory diseases. Trajectory analysis was employed to identify a gradient of Wnt expression across fibroblast populations. We developed Wnt activation signatures using in vitro stimulation of human RA-derived synovial fibroblast lines treated with canonical and non-canonical Wnt ligands.

Results: Among all synovial cell populations, Wnt pathway members are predominantly expressed in fibroblast subsets. These molecules include Frizzed receptors, LRP5/6 co-receptors, R-spondin (RSPO) Wnt agonists, and Dickkopf (DKK) Wnt antagonists. Interestingly, non-canonical Wnt ligands dominate in expression as do RSPO3 and DKK3 (Figure 1A and 1B). Strikingly, RSPO3 and DKK3 are expressed reciprocally in distinct populations. Instead of being cluster-specific, RSPO3 and DKK3 form a strong gradient along both lining and sublining fibroblasts (Figure 1C). Using trajectory analysis, we demonstrate that RSPO3 and DKK3 correlate with genes that are differentially associated with inflammation and tissue repair, respectively (Figure 2A and 2B). To explore Wnt pathway activity along this gradient, we generated a non-canonical Wnt activation signature using synovial fibroblasts stimulated with Wnt5a. This signature reveals that non-canonical Wnt signaling drives fibroblast inflammation (Figure 2C) and is particularly active among cells expressing Wnt agonist RSPO3 (Figure 2D). The Wnt5a and RSPO3 gene signatures are also enhanced in fibroblasts derived from inflamed RA synovial tissue compared with those from OA synovial tissue while the DKK3 signature is reduced, suggesting increased Wnt activity in inflammatory RA (Figure 2E). Moreover, analyses show comparable Wnt-mediated gradients in Sjogren’s syndrome and interstitial lung disease, indicating broader disease applicability.

Conclusion: We identify non-canonical Wnt signaling as a novel mechanism contributing to RA synovial fibroblast heterogeneity and inflammatory phenotype. This work provides a foundation for the development of Wnt-modulating pharmacologic strategies targeting synovial fibroblasts in RA.

Figure 1: Synovial fibroblasts are poised for Wnt signaling, and expression of Wnt agonist RSPO3 is inversely correlated with Wnt antagonist DKK3 among fibroblast subpopulations. A) Expression of Wnt receptors, co-receptors, activators, and inhibitors from bulk RNA sequencing of synovial populations in OA and RA patients are predominantly expressed in fibroblasts. (B) Single-cell sequencing analyses of synovial cells from OA and RA patients confirms fibroblast-specific expression of a number of Wnt pathway members including DKK3 and RSPO3. (C) DKK3 and RSPO3 exhibit reciprocal patterns of expression within synovial fibroblast subpopulations in independent studies.

Figure 2: RSPO3 and DKK3 define a transcriptional gradient that is correlated with Wnt activity and inflammation. A) Trajectory analysis identifies genes that follow expression patterns that are similar to RSPO3 and DKK3 (B) Genes associated with RSPO3 show enrichment for cell growth, migration, and cytokine signaling while genes associated with DKK3 are linked to structural collagen components and extracellular matrix. (C) Differential expression analysis of synovial fibroblasts treated with Wnt5a compared with controls reveals that non-canonical Wnt signaling is associated with genes that drive inflammatory pathways. (D) RSPO3 expression is correlated with higher non-canonical Wnt activity. (E) Human fibroblasts isolated from leukocyte-rich RA synovial tissue show enhanced Wnt activity scores and RSPO3 enrichment scores compared with synovial fibroblasts isolated from OA samples.


Disclosures: A. Mueller, None; A. Zou, None; E. Taylor, None; T. Major, None; D. Gardner, None; A. Croft, None; R. Fibroblast Network Consortium, Roche, 3; A. Filer, GSK, 5, Mestag, 5, Galapagos, 2, 5, Janssen, 5, Roche, 5, Nascient, 5; C. Buckley, None; K. Wei, Mestag, 2; I. Korsunsky, Mestag Therapeutics, 2; S. Raychaudhuri, Mestag Therapeutics, 2, 12, Founder, Johnson & Johnson, 1, 2, Pfizer, 1, 2, Biogen, 5, Gilead Sciences, 2; M. Brenner, GSK, 2, 4FO Ventures, 2, Mestag Therapeutics, 2, 11.

To cite this abstract in AMA style:

Mueller A, Zou A, Taylor E, Major T, Gardner D, Croft A, Fibroblast Network Consortium R, Filer A, Buckley C, Wei K, Korsunsky I, Raychaudhuri S, Brenner M. Single Cell Profiling Reveals a Wnt-mediated Transcriptional Gradient That Drives Inflammation in Rheumatoid Arthritis Synovial Fibroblast Pathology [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/single-cell-profiling-reveals-a-wnt-mediated-transcriptional-gradient-that-drives-inflammation-in-rheumatoid-arthritis-synovial-fibroblast-pathology/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/single-cell-profiling-reveals-a-wnt-mediated-transcriptional-gradient-that-drives-inflammation-in-rheumatoid-arthritis-synovial-fibroblast-pathology/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology